The Company was founded in 1999 by six immunologists, including Hervé Brailly, the current Chairman of the Executive Board, and François Romagné, a member of the Executive Board and Chief Scientific Officer. The other founding members are French and Italian scientists who have made significant contributions in the area of unconventional lymphocyte biology, the science at the basis of the first two drug candidates of the Company.

These founders have brought the original intellectual propriety basis of Innate Pharma, thought licensing, research and collaboration agreements with academic institutions, most notably Inserm and the University of Genoa in Italy.

All along its history, the Company has strengthens its intellectual propriety, built an internal expertise by recruiting highly qualified collaborators and developed a rich and diverse portfolio of drug-candidates. The Company has grown though financing from venture capital, industrial partnership and its IPO in 2006.

The key date of Innate Pharma’s history are summarized below:

1999: Company inception

2001: First drug candidate in development
 

2002: First clinical trial

2003: First collaboration and licensing deal with Novo Nordisk A/S for the development of IPH 2101

2006: Second collaboration and licensing agreement with Novo Nordisk A/S comprising all of the drug candidates targeting NK cells. First Phase II clinical trial. Initial public offering (“IPO”) on the NYSE-Euronext market in Paris (33.7 million euros raised)

2008: Acquisition of rights to IPH 2101 from Novo Nordisk A/S through an asset transfer agreement

2009: Capital increase of 24.3 million euros reserved to categories of investors